Company news

Pliant Therapeutics, Inc. news in 2024

Pliant Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Pliant Therapeutics to Participate in Upcoming Investor Events

November 20, 2024

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

November 17, 2024

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 6, 2024

Pliant Therapeutics to Participate in the Stifel Healthcare Conference

November 5, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024

October 16, 2024

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

September 30, 2024

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

September 9, 2024

Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024

August 25, 2024

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 6, 2024

Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

August 5, 2024

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures

July 14, 2024

Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

June 12, 2024

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

June 5, 2024

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

May 20, 2024

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

May 13, 2024

Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™

May 6, 2024

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 5, 2024

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

March 26, 2024

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

March 11, 2024

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

February 26, 2024

Pliant Therapeutics to Participate in Upcoming Investor Conferences

February 25, 2024

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

February 3, 2024

Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Decks in 2024